Organization: Bharat Biotech International Ltd
CMD: Dr Krishna M Ella
Bioscience Revenue: Rs 308.16 crore
Bharat Biotech has clocked a turnover of Rs 308.16 crore in the fiscal 2014-15, from Rs 270.34 crore, a growth of 14 percent from the FY 2013-14. The CMD, Dr Krishna Ella with his vision to develop high technology products at an affordable pricing has achieved the success by launching India's first indigenously developed Rotavirus Vaccine "Rotavac" in the market. The vaccine was launched by Prime Minister Mr Narendra Modi. This announcement fulfilled Bharat Biotech's promise of a $1 per dose vaccine to governments in low-income countries. The company has received commercial licensure and the vaccine is safe to use.
The firm attributes its success to the helping hand extended by the Government of India and Bill & Melinda Gates Foundation in developing vaccines by keeping in view under privileged people in developing countries.
The other major developments include, signing off large grant proposal with Bill & Melinda Gates Foundation and also a co-marketing agreement with a multinational company.
As a key strategy initiatives for the last fiscal, the company got its products and manufacturing facilities approved by the WHO. In this direction, it also has started filing application for the WHO PQ for multiple products and facilities. The company's future plans for the FY2015-16 include getting international regulatory approvals for its existing products.
With over 50 technology-driven patents, Hyderabadbased Bharat Biotech is a multi-dimensional biotechnology company involved in quality product-oriented research and development. The company is presently carrying out research on Bio-Antibiotics, Combination Probiotics, Lysostaphin, THR-100 (Recombinant Staphylokinase Injection), Chikungunya Vaccine, Typhoid Conjugate Vaccine, Oral Rotavirus Vaccine, Malaria Vaccine, Liquid Rabies Vaccine and Staphylococcus aureus vaccine.